US 2006/0233796 A1Published application

Method of modulating memory effector T-cells and compositions

AssigneeBiogen Idec MA Inc., a Massachusetts corporation

InventorDaniel Magilavy

Life of this patent

Estimating the term…

Abstract

This invention relates to methods of using inhibitors of the CD2/LFA-3 interaction in treating conditions characterized by the presence of activated T cells in mammals, including humans. Such conditions include inflammatory bowel diseases, psoriatic arthritis, rheumatoid arthritis, and multiple sclerosis.

Claims2

Dependent claims

A method for selectively modulating memory effector T lymphocytes in a subject having a medical condition, the method comprising administering to the subject an effective amount of a CD2 binding agent.

Dependencies are inferred from the claim text.

Facts

Application: 11/398,908Filed 6 Apr 2006
Priority: 31 Aug 1998
Published: 19 Oct 2006
Term ends: Not estimatedThe source records don’t support an estimate.

Classification19 codes

C07K 14/70507
Immunoglobulin superfamily: cd2
A61K 38/1774
Receptors; Cell surface antigens; Cell surface determinants: immunoglobulin superfamily
A61P 1/00
Drugs for disorders of the alimentary tract or the digestive system
A61P 1/04
Drugs for disorders of the alimentary tract or the digestive system: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of…

Family

Application60/098,456Us provisional application · filed 31 Aug 1998
Application09/796,033Continuation · filed 27 Feb 2001
Application11/398,908Continuation · filed 6 Apr 2006
US 2002/0009446 A1Published application
US 2006/0233796 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results